

AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended)

A pharmaceutical composition consisting essentially of, as the separate active ~~ingredient~~ ingredients, a NO synthase inhibitory substance and a metabolic antioxidant substance possessing at least two thiol groups and which intervene(s) in the redox status of thiol groups, and optionally a pharmaceutically acceptable support, said composition having the dual activity of inhibiting the NO synthase antioxidant.

Claims 2-3 (cancelled)

Claim 4 (previously presented)

A pharmaceutical composition of claim 1 wherein the metabolix antioxidant is selected from the group consisting of dithiothreitol, pyritinol, lipoic acid and its derivatives, the dimeric disulfide derivatives of penicillamine or N-acetylcysteine, and peptides comprising at least two cysteine residues.

Claims 5 to 7 (cancelled)

Claim 8 (previously presented)

A pharmaceutical composition of claim 1 wherein the NO synthase inhibitor is selected from the group consisting of a compound of amino acid type, a compound of the guanidine isothiurea, nitro- and cyano-aryl, amino-pyridine, amino-pyrimidone,

amidine, indazole and imidazole families.

Claim 9 (previously presented)

A pharmaceutical composition of claim 8 wherein the NO synthase inhibitor of amino-acid type is selected from the group consisting of L-arginine, ornithine and lysine derivatives.

Claim 10 (previously presented)

A pharmaceutical composition of claim 1 wherein the NO synthase inhibitor is selected from the group consisting of L-nitro-arginine, L-nitro-arginine methyl ester, L-N-monomethylarginine, aminoguanidine, agmatine, 2-amino-1-(methylamino)benzimidazole, 5-nitro-indazole, 6-nitro-indazole, 7-nitro-indazole, 1,2-(trifluoromethylphenyl)phenylimidazole, 2-amino-4-methyl-6-(2-aminoethyl)pyridine, 2-iminopiperidine, 2-iminohomopiperidine, 2-imino-5,6-dihydro-1,3-thiazine, 2-imino-5,6-dihydro-1,3-oxazine, 2-iminotetrahydropyrimidine, N-phenyl-2-thiophene-carboximidamine, S-ethylisothiouraea, S-methyl-L-thiocitrulline and S-ethyl-L-thiocitrulline.

Claim 11 (previously presented)

A pharmaceutical composition of claim 1 wherein the metabolic antioxidant is lipoic acid in racemic or enantiomeric form.

Claim 12 (previously presented)

A pharmaceutical composition of claim 1 wherein the NO synthase inhibitor is a neuronal and/or inducible NO synthase inhibitor.

Claims 13-24 (cancelled)

Claim 25-36 (cancelled)